Yun Shim, MD
Critical Care Medicine · Charlottesville, VANPI 1265575138
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,759 of the $3,899 with a category attached, or 96.4%. AstraZeneca accounts for 96.4% of it on its own, with 2 other manufacturers making up the rest.
Across 4 payments — averaging $974.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Genentech USA, Inc.$125
- Genentech, Inc.$15
Across 43 payments — averaging $13,129 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$510K
- AstraZeneca$54K
What the payments were for
- Consulting fees$3,75996%
- Food & beverage$1404%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $3,759 |
| Genentech USA, Inc. | 1 | $125 |
| Genentech, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,899 in reported general payments places this provider in the 80th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $81,241 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $37,348 |
| Dupixent PenDupilumab | 11 | $36,838 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $34,740 |
| Spiriva RespimatTiotropium Bromide | 23 | $24,630 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $12,138 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $6,061 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,905 |
| Roflumilast | 40 | $4,136 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,332 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,328 |
| Ventolin HfaAlbuterol Sulfate | 23 | $2,225 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 11 | $737 |
| Montelukast Sodium | 33 | $422 |
| Prednisone | 68 | $336 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Charlottesville
- Robert ThieleCharlottesville$52K
- Clinton WilkinsonCharlottesville$9K
- Taison BellCharlottesville$7K
- Michael MazzeffiCharlottesville$7K
- Akram ZaaqoqCharlottesville$6K
- Matthew HulseCharlottesville$3K
- Danny TheodoreCharlottesville$3K
- Joshua MakepeaceCharlottesville$1K
- David StombaughCharlottesville$823
- Samuel OliverCharlottesville$789
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.